Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients
Jan C. Thomassen, Matthias I. Mueller, Miguel A. Alejandre Alcázar, et al.
Journal of Cystic Fibrosis (2017) Vol. 17, Iss. 2, pp. 271-275
Closed Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status
Chenglin Hu, Yuan Chen, Xinpeng Yin, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis
Andrea Granados, Christine L. Chan, Katie Larson Ode, et al.
Journal of Cystic Fibrosis (2019) Vol. 18, pp. S3-S9
Open Access | Times Cited: 125
The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis
Valentine Sergeev, Frank Y. Chou, Grace Y. Lam, et al.
Annals of the American Thoracic Society (2019) Vol. 17, Iss. 2, pp. 147-154
Open Access | Times Cited: 89
The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis
Kevin J. Scully, Peter Marchetti, Gregory S. Sawicki, et al.
Journal of Cystic Fibrosis (2021) Vol. 21, Iss. 2, pp. 258-263
Open Access | Times Cited: 63
Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis
Kevin W Southern, Carlo Castellani, Elise Lammertyn, et al.
Journal of Cystic Fibrosis (2022) Vol. 22, Iss. 1, pp. 17-30
Open Access | Times Cited: 51
Effect of one-year lumacaftor–ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients
Bastien Misgault, Eva Chatron, Quitterie Reynaud, et al.
Journal of Cystic Fibrosis (2020) Vol. 19, Iss. 5, pp. 712-716
Open Access | Times Cited: 59
Effect of CFTR modulator therapy on cystic fibrosis-related diabetes
Holly Gaines, Kellie Jones, Jonea Lim, et al.
Journal of Diabetes and its Complications (2021) Vol. 35, Iss. 6, pp. 107845-107845
Open Access | Times Cited: 42
Current state of CFTR modulators for treatment of Cystic Fibrosis
Katherine A. Despotes, Scott H. Donaldson
Current Opinion in Pharmacology (2022) Vol. 65, pp. 102239-102239
Open Access | Times Cited: 31
Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study
Insa Korten, Elisabeth Kieninger, Linn Krueger, et al.
Frontiers in Pediatrics (2022) Vol. 10
Open Access | Times Cited: 29
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients
Amir Moheet, Daniel Beisang, Lin Zhang, et al.
Journal of Cystic Fibrosis (2020) Vol. 20, Iss. 2, pp. 333-338
Open Access | Times Cited: 48
Cardiovascular complications in cystic fibrosis: A review of the literature
T. Spencer Poore, Jennifer L. Taylor‐Cousar, Edith T. Zemanick
Journal of Cystic Fibrosis (2021) Vol. 21, Iss. 1, pp. 18-25
Open Access | Times Cited: 40
Cystic Fibrosis–Related Diabetes: Pathophysiology and Therapeutic Challenges
R.C. Kelsey, Fiona N. Manderson Koivula, Neville H. McClenaghan, et al.
Clinical Medicine Insights Endocrinology and Diabetes (2019) Vol. 12
Open Access | Times Cited: 42
Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor
Angel Li, Tim Vigers, Laura Pyle, et al.
Journal of Cystic Fibrosis (2018) Vol. 18, Iss. 1, pp. 144-149
Open Access | Times Cited: 40
Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients
Katherine Kutney, Shannon Donnola, Chris A. Flask, et al.
World Journal of Hepatology (2019) Vol. 11, Iss. 12, pp. 761-772
Open Access | Times Cited: 39
Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis
Anh-Thu N. Lam, Melis A. Aksit, Briana Vecchio-Pagán, et al.
Journal of Clinical Investigation (2019) Vol. 130, Iss. 1, pp. 272-286
Open Access | Times Cited: 37
The role of modulators in cystic fibrosis related diabetes
Lina Merjaneh, S. N. Hasan, Nader Kasim, et al.
Journal of Clinical & Translational Endocrinology (2021) Vol. 27, pp. 100286-100286
Open Access | Times Cited: 31
Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes
F. Lurquin, Sophie Gohy, Michel P. Hermans, et al.
Journal of Clinical & Translational Endocrinology (2023) Vol. 33, pp. 100320-100320
Open Access | Times Cited: 11
Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis
Bernadette Prentice, Avinesh Chelliah, Chee Y. Ooi, et al.
Journal of Cystic Fibrosis (2019) Vol. 19, Iss. 2, pp. 305-309
Open Access | Times Cited: 33
Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
Carla Colombo, Andrea Foppiani, Arianna Bisogno, et al.
Journal of Endocrinological Investigation (2021) Vol. 44, Iss. 10, pp. 2213-2218
Open Access | Times Cited: 27
Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis
Claudia Piona, Enza Mozzillo, Antonella Tosco, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 14, pp. 4149-4149
Open Access | Times Cited: 17
Cystic fibrosis–related diabetes onset can be predicted using biomarkers measured at birth
Yu-Chung Lin, Katherine Keenan, Jiafen Gong, et al.
Genetics in Medicine (2021) Vol. 23, Iss. 5, pp. 927-933
Open Access | Times Cited: 21
The Potential Causes of Cystic Fibrosis-Related Diabetes
Lise Coderre, Lyna Debieche, J. R. Plourde, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 21
CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
Hanna Crow, Charles D. Bengtson, Xiaosong Shi, et al.
Journal of Clinical & Translational Endocrinology (2022) Vol. 30, pp. 100307-100307
Open Access | Times Cited: 16
Advances in cystic fibrosis-related diabetes: Current status and future directions
F. Lurquin, Martin Buysschaert, Vanessa Preumont
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 11, pp. 102899-102899
Open Access | Times Cited: 8
Glycemia and β-cell function before and after elexacaftor/tezacaftor/ivacaftor in youth and adults with cystic fibrosis
Christine L. Chan, Andrea Granados, Amir Moheet, et al.
Journal of Clinical & Translational Endocrinology (2022) Vol. 30, pp. 100311-100311
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top